WO2014010281A1 - 眼疾患の予防・治療薬 - Google Patents
眼疾患の予防・治療薬 Download PDFInfo
- Publication number
- WO2014010281A1 WO2014010281A1 PCT/JP2013/060460 JP2013060460W WO2014010281A1 WO 2014010281 A1 WO2014010281 A1 WO 2014010281A1 JP 2013060460 W JP2013060460 W JP 2013060460W WO 2014010281 A1 WO2014010281 A1 WO 2014010281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- dry eye
- muc5ac
- tissue
- prophylactic
- Prior art date
Links
- XQIWSKNLGVBWNR-UHFFFAOYSA-N OCC(C(N(CC1)C2C1O)=O)NC2=O Chemical compound OCC(C(N(CC1)C2C1O)=O)NC2=O XQIWSKNLGVBWNR-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a prophylactic / therapeutic agent for eye diseases. More specifically, the present invention relates to a prophylactic / therapeutic agent for dry eye and a mucin secretion promoter.
- Dry eye is a chronic disease of tears and keratoconjunctival epithelium due to various factors, and is an eye disease accompanied by eye discomfort and abnormal visual function.
- the treatment for dry eye was limited to sodium hyaluronate instillation and artificial tears.
- a drug that promotes mucin secretion from the conjunctival tissue containing diquafosol sodium or rebamipide as an active ingredient It came to be marketed.
- mucins Muc5ac is a protein secreted from goblet cells of the conjunctival tissue of the eye, and is an important component constituting tears. Mucin loss is a factor in dry eye.
- cyclo-trans-4-L-hydroxyprolyl-L-serine is a hydroxyproline derivative and has cell proliferation action and cell protection action (Patent Document 1), prevention of allergic diseases and inflammatory diseases. -It is known that it is effective for treatment (Patent Documents 2 and 3).
- An object of the present invention is to provide a novel preventive / therapeutic agent for eye diseases, and more particularly, to provide a prophylactic / therapeutic agent for dry eye, particularly for promoting mucin secretion and dry eye. It is an object of the present invention to provide a prophylactic / therapeutic agent for dry eye having an action of promoting the repair of ocular tissue damage caused by the damage.
- cyclo-trans-4-L-hydroxyprolyl-L-serine (hereinafter also referred to as compound 1) promotes mucin secretion in a concentration-dependent manner.
- the mucin secretion promoting action of Compound 1 is completely different from the known action of Compound 1, and it was an unexpected result to have such an action.
- Compound 1 also promotes repair of eye tissue damage caused by dry eye.
- Patent Document 1 describes that Compound 1 is useful for tissue repair and regeneration, but only describes a hepatoprotective action, and does not mention any repair of ocular tissue.
- the liver and eyes are completely different tissues, and their repair and regeneration mechanisms are also completely different. Therefore, the repair promoting action of eye tissue damage caused by dry eye of Compound 1 is an unexpected action.
- the present inventors have completed the present invention. That is, the present invention provides a prophylactic / therapeutic agent for dry eye comprising Compound 1 as an active ingredient.
- the present invention provides a prophylactic / therapeutic agent for dry eye caused by mucin reduction, comprising Compound 1 as an active ingredient.
- the prophylactic / therapeutic agent for dry eye of the present invention also promotes repair of eye tissue damage caused by dry eye.
- the present invention also provides a mucin secretion promoter containing Compound 1 as an active ingredient.
- the present invention further provides the following (1) to (12).
- (1) A method for preventing and treating dry eye comprising administering an effective amount of cyclo-trans-4-L-hydroxyprolyl-L-serine to a patient.
- (3) A method for promoting mucin secretion comprising administering an effective amount of cyclo-trans-4-L-hydroxyprolyl-L-serine to a patient.
- a method for promoting the repair of ocular tissue damage caused by dry eye comprising administering an effective amount of cyclo-trans-4-L-hydroxyprolyl-L-serine to a patient.
- Cyclo-trans-4-L-hydroxyprolyl-L-serine for use in the prevention and treatment of dry eye.
- Cyclo-trans-4-L-hydroxyprolyl-L-serine for use in the prevention and treatment of dry eye caused by mucin reduction.
- Cyclo-trans-4-L-hydroxyprolyl-L-serine for use in promoting mucin secretion.
- Cyclo-trans-4-L-hydroxyprolyl-L-serine for use in promoting the repair of ocular tissue damage caused by dry eye.
- a novel prophylactic / therapeutic agent for eye diseases is provided. More specifically, a prophylactic / therapeutic agent for dry eye, a prophylactic / therapeutic agent for dry eye caused by mucin reduction, and a dry eye Provided are a prophylactic / therapeutic agent for dry eye and a mucin secretion promoter that promote repair of eye tissue damage.
- FIG. 3 is a diagram showing an in vivo Muc5ac secretion promoting effect by compound 1.
- A is the result of quantifying Muc5ac secreted into the culture supernatant by ELISA. The total represents the total amount of Muc5ac quantified at 0-1.5 hours and 1.5-3 hours.
- (B) is the result of quantifying the amount of Muc5ac protein in the conjunctival tissue. It is the result of the PAS dyeing
- FIG. 1 is the result of quantifying the amount of Muc5ac protein in the conjunctival tissue. It is the result of the PAS dyeing
- the present invention provides a prophylactic / therapeutic agent for dry eye comprising Compound 1 as an active ingredient.
- a prophylactic / therapeutic agent for dry eye comprising Compound 1 as an active ingredient.
- the compound 1 is a compound represented by the following chemical formula (1).
- Compound 1 may be in a free form or may form a pharmaceutically acceptable salt.
- the manufacturing method of the compound 1 is not specifically limited, For example, it can obtain by the method of patent document 1 and 3.
- the prophylactic / therapeutic agent for dry eye containing Compound 1 according to the present embodiment as an active ingredient can be used by mixing with pharmacologically necessary ingredients such as appropriate pharmaceutically acceptable additives.
- pharmacologically necessary ingredients such as appropriate pharmaceutically acceptable additives.
- additives are, for example, carriers, excipients, pH adjusters and diluents.
- the form of the above-mentioned prophylactic / therapeutic agent for dry eye is not particularly limited, and it is preferably prepared as a pharmaceutical preparation in the form of eye drops, internal medicine, or injection.
- the content of Compound 1 in the preparation can be appropriately adjusted by those skilled in the art, and the preparation method of the preparation is not particularly limited, and a known method can be used.
- the effective dose and administration schedule of such dry eye prophylactic / therapeutic agents can be appropriately determined by those skilled in the art depending on the administration method, medical condition, patient weight and age, and the like.
- Compound 1 Since Compound 1 has a mucin promoting action, it is particularly effective for a prophylactic / therapeutic agent for dry eye caused by mucin reduction.
- mucin is not specifically limited, For example, Muc5ac is mentioned.
- the prophylactic / therapeutic agent for dry eye of the present invention also promotes repair of eye tissue damage caused by dry eye.
- the prophylactic / therapeutic agent for dry eye according to the present embodiment can also promote wound healing of eye tissue damage caused by dry eye.
- the ocular tissue is not particularly limited as long as it constitutes the eye, and is preferably the cornea or the conjunctiva, and more preferably the corneal epithelial tissue or the conjunctival epithelial tissue.
- the present invention also provides a mucin secretion promoter comprising Compound 1 as an active ingredient.
- a mucin secretion promoter comprising Compound 1 as an active ingredient.
- Example 1 Effect of compound 1 on Muc5ac secretion
- Slc JW / CSKSlc: NZW strain
- the amount of Muc5ac contained in the culture supernatant was detected using the following measurement method.
- washing buffer was prepared by adding Tween-20 to Tris buffered saline (pH 7.6) to a final concentration of 0.05% (hereinafter also referred to as TBST solution).
- blocking buffer TST solution containing 1% bovine serum albumin
- 100 ⁇ L / well of a primary antibody solution anti-human Muc5ac antibody, NeoMarkers, Clone 45M1 diluted 100 times with the blocking buffer was added and incubated at room temperature for 1 hour. After removing the primary antibody solution, the wells were washed 3 times with 200 ⁇ L wash buffer.
- a secondary antibody solution (HRP-labeled sheep anti-mouse IgG antibody, manufactured by GE Healthcare) diluted 2000 times with blocking buffer was added at 100 ⁇ L / well and incubated at room temperature for 1 hour. After removing the secondary antibody solution, the wells were washed 3 times with 200 ⁇ L wash buffer.
- Example 2 Concentration dependence of Muc5ac secretion amount on Compound 1
- White rabbit rabbit conjunctival tissue was sampled using a 3 mm diameter trepan and immersed in HBSS containing 0, 1, 10 and 100 ⁇ M of compound 1.
- the amount of Muc5ac contained in the culture supernatant was detected using the ELISA method in the same manner as in Example 1.
- Compound 1 has an action of promoting mucin secretion in the conjunctival tissue.
- Example 3 Effect of compound 1 on wound treatment of corneal epithelial tissue
- in vivo experiments using white rabbits Slc: JW / CSKSlc: NZW strain
- the corneal epithelial tissue was stained with fluorescein using physiological saline and a fluorescein test paper, and the temporal change of the wound area of the corneal epithelium was photographed and observed.
- the wound area was subjected to statistical analysis by image processing using Image J software.
- Example 4 Promotion of in vivo Muc5ac secretion action by compound 1
- in vivo experiments using white rabbits Slc: JW / CSKSlc: NZW strain
- a 100 ⁇ M compound 1 solution dissolved in physiological saline was instilled into the right eye of a white rabbit four times a day at a dose of 30 ⁇ L to 50 ⁇ L / dose.
- physiological saline was administered as an ophthalmic solution four times a day at a dose of 30 ⁇ L to 50 ⁇ L / dose.
- the white rabbit was euthanized and the conjunctival tissue was sampled with 5 mm trepan.
- the sample was immersed in HBSS, and the culture supernatant was collected after 1.5 hours, and the culture supernatant and conjunctival tissue were further collected after 3 hours.
- the amount of Muc5ac contained in the culture supernatant was quantified using the ELISA method in the same manner as in Example 1. The result is shown in FIG. It was revealed that the amount of Muc5ac contained in the culture supernatant of conjunctival tissue collected from the compound 1 administration group was significantly higher than that of the subject group.
- the amount of Muc5ac protein in the conjunctival tissue collected from the compound 1 administration group is almost the same as that in the control group. This result, together with the result that the amount of Muc5ac secreted from the compound 1 administration group was significantly higher than that of the control group, indicates that compound 1 has an action of promoting mucin synthesis and secretion. .
- PAS staining for staining neutral polysaccharides and glycoprotein species was performed on the conjunctival tissues of the control group and the administration group. Specifically, conjunctival tissue was collected from rabbits, and the collected conjunctival tissue was cut into upper, nasal, lower, and ear regions, and paraffin sections were made. Next, for deparaffinization, the slices were washed with distilled water, soaked in 3% aqueous acetic acid, and immersed in Alcian blue liquor for 30 minutes. The section was washed with distilled water, immersed in a 1% periodic acid aqueous solution for 10 minutes, washed with running water for 5 minutes, and washed with distilled water.
- the section was immersed in Cold Schiff solution for 10 minutes, and then immersed in sulfite water for 3 minutes, and treated with sulfite water. After this treatment was repeated three times, the sections were washed with running water for 5 minutes and immersed in Mayer's hematoxylin solution for 3 to 5 minutes to stain cell nuclei. The sections were washed with running water for 10 minutes for coloration, and then dehydrated and permeabilized for encapsulation. Sections were observed using a microscope and photographs were taken.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
(1)有効量のシクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを患者に投与する、ドライアイの予防・治療方法。
(2)有効量のシクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを患者に投与する、ムチン減少に起因するドライアイの予防・治療方法。
(3)有効量のシクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを患者に投与する、ムチン分泌の促進方法。
(4)有効量のシクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを患者に投与する、ドライアイに起因する眼組織損傷の修復を促進する方法。
(5)ドライアイの予防・治療に使用するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリン。
(6)ムチン減少に起因するドライアイの予防・治療に使用するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリン。
(7)ムチン分泌の促進に使用するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリン。
(8)ドライアイに起因する眼組織損傷の修復促進に使用するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリン。
(9)ドライアイの予防・治療薬を製造するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンの使用。
(10)ムチン減少に起因するドライアイの予防・治療薬を製造するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンの使用。
(11)ムチン分泌促進剤を製造するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンの使用。
(12)ドライアイに起因する眼組織損傷の修復促進剤を製造するための、シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンの使用。
化合物1のMuc5ac分泌量に対する影響を確認するため、白色家兎(Slc:JW/CSKSlc:NZW系統)の結膜組織を用いたex vivo実験を行った。
まず、対照群の結膜組織の培養上清を、HBSSを用いて希釈し、それぞれのMuc5acの濃度が500、250、125、62.5、31.25、15.63、7.81AU/mL(AUは任意単位を表す。)となるように検量線を調製した。サンプル溶液は、波長450nmにおける吸光度が検量線の波長450nmにおける吸光度の範囲内になるようにHBSSで希釈した。次に、検量線溶液、試験群のサンプル溶液及び対象群のサンプル溶液を、96ウェルのマイクロプレート(Corning社製、#3590)に100μL/ウェルで添加し、40℃で一晩インキュベートした。測定は、各サンプルについてn=2で行った。
3mm径のトレパンを用いて白色家兎の結膜組織をサンプリングし、0、1、10及び100μMの化合物1を含有するHBSS中に浸漬した。対照群の結膜組織は、化合物1と同等の量の生理食塩水を添加したHBSS中に浸漬した。結膜組織を6時間浸漬した後、培養上清を採取した。実験は、各郡についてn=5で行った。
化合物1による角膜上皮組織の創傷治療効果を確認するため、白色家兎(Slc:JW/CSKSlc:NZW系統)を用いたin vivo実験を行った。
化合物1によるMuc5ac分泌作用促進を確認するため、白色家兎(Slc:JW/CSKSlc:NZW系統)を用いたin vivo実験を行った。
Claims (4)
- シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを有効成分とする、ドライアイの予防・治療薬。
- シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを有効成分とする、ムチン減少に起因するドライアイの予防・治療薬。
- シクロ-トランス-4-L-ヒドロキシプロリル-L-セリンを有効成分とする、ムチン分泌促進剤。
- ドライアイに起因する眼組織損傷の修復を促進する、請求項1又は2に記載のドライアイの予防・治療薬。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13816538.6T ES2621898T3 (es) | 2012-07-09 | 2013-04-05 | Medicamento para la prevención/tratamiento de enfermedades oculares |
EP13816538.6A EP2870971B1 (en) | 2012-07-09 | 2013-04-05 | Drug for preventing/treating ocular disease |
JP2013552051A JP5782638B2 (ja) | 2012-07-09 | 2013-04-05 | 眼疾患の予防・治療薬 |
US14/413,455 US9555028B2 (en) | 2012-07-09 | 2013-04-05 | Drug for preventing/treating ocular disease |
KR1020157002946A KR101710349B1 (ko) | 2012-07-09 | 2013-04-05 | 안질환의 예방·치료약 |
CN201380036285.8A CN104487080B (zh) | 2012-07-09 | 2013-04-05 | 眼病的预防/治疗药 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-153729 | 2012-07-09 | ||
JP2012153729 | 2012-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014010281A1 true WO2014010281A1 (ja) | 2014-01-16 |
Family
ID=49915758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/060460 WO2014010281A1 (ja) | 2012-07-09 | 2013-04-05 | 眼疾患の予防・治療薬 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9555028B2 (ja) |
EP (1) | EP2870971B1 (ja) |
JP (1) | JP5782638B2 (ja) |
KR (1) | KR101710349B1 (ja) |
CN (1) | CN104487080B (ja) |
ES (1) | ES2621898T3 (ja) |
WO (1) | WO2014010281A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015166555A1 (ja) * | 2014-04-30 | 2015-11-05 | 株式会社日本生物製剤 | 涙液分泌促進剤、及び涙液分泌減少に起因するドライアイの予防・治療薬 |
WO2019065936A1 (ja) * | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | 涙液中のmuc5ac量の測定方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116041419A (zh) * | 2021-10-28 | 2023-05-02 | 苏州裕泰医药科技有限公司 | 羟脯氨酰基-丝氨酸化合物及其制备和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288106A (ja) * | 2000-04-10 | 2001-10-16 | Nippon Seibutsu Seizai:Kk | 炎症性疾患治療剤 |
JP2003313127A (ja) * | 2002-04-22 | 2003-11-06 | Nippon Seibutsu Seizai:Kk | アレルギー性疾患治療用外用剤 |
JP3969831B2 (ja) | 1997-03-15 | 2007-09-05 | 株式会社日本生物製剤 | ハイドロキシプロリン誘導体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635620B1 (en) * | 1998-03-16 | 2003-10-21 | Japan Bioproducts Ind. Co., Ltd. | Hydroxyproline derivatives |
JP2006176499A (ja) | 2004-11-25 | 2006-07-06 | Nippon Seibutsu Seizai:Kk | 眼疾患治療剤 |
-
2013
- 2013-04-05 EP EP13816538.6A patent/EP2870971B1/en active Active
- 2013-04-05 US US14/413,455 patent/US9555028B2/en active Active
- 2013-04-05 ES ES13816538.6T patent/ES2621898T3/es active Active
- 2013-04-05 CN CN201380036285.8A patent/CN104487080B/zh active Active
- 2013-04-05 JP JP2013552051A patent/JP5782638B2/ja active Active
- 2013-04-05 WO PCT/JP2013/060460 patent/WO2014010281A1/ja active Application Filing
- 2013-04-05 KR KR1020157002946A patent/KR101710349B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3969831B2 (ja) | 1997-03-15 | 2007-09-05 | 株式会社日本生物製剤 | ハイドロキシプロリン誘導体 |
JP2001288106A (ja) * | 2000-04-10 | 2001-10-16 | Nippon Seibutsu Seizai:Kk | 炎症性疾患治療剤 |
JP4601118B2 (ja) | 2000-04-10 | 2010-12-22 | 株式会社日本生物製剤 | 炎症性疾患治療剤 |
JP2003313127A (ja) * | 2002-04-22 | 2003-11-06 | Nippon Seibutsu Seizai:Kk | アレルギー性疾患治療用外用剤 |
JP4253161B2 (ja) | 2002-04-22 | 2009-04-08 | 株式会社日本生物製剤 | アレルギー性疾患治療用外用剤 |
Non-Patent Citations (5)
Title |
---|
ARGUESO P ET AL.: "Analysis of human ocular mucus: effects of neuraminidase and chitinase enzymes.", CORNEA., vol. 17, no. 2, March 1998 (1998-03-01), pages 200 - 207, XP008176091 * |
CLAUDIO BUCOLO ET AL.: "Acidic mammalian chitinase in dry eye conditions.", CORNEA, vol. 28, no. 6, July 2009 (2009-07-01), pages 667 - 672, XP055184821 * |
HOUSTON DR ET AL.: "Structure-based exploration of cyclic dipeptide chitinase inhibitors.", J MED CHEM., vol. 47, no. 23, 4 November 2004 (2004-11-04), pages 5713 - 5720, XP003014252 * |
See also references of EP2870971A4 * |
THE MERCK MANUAL JAPANESE EDITION, 10 December 1999 (1999-12-10), pages 719 - 720, XP008176330 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015166555A1 (ja) * | 2014-04-30 | 2015-11-05 | 株式会社日本生物製剤 | 涙液分泌促進剤、及び涙液分泌減少に起因するドライアイの予防・治療薬 |
WO2019065936A1 (ja) * | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | 涙液中のmuc5ac量の測定方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101710349B1 (ko) | 2017-02-27 |
EP2870971A1 (en) | 2015-05-13 |
EP2870971B1 (en) | 2017-03-08 |
KR20150100603A (ko) | 2015-09-02 |
JPWO2014010281A1 (ja) | 2016-06-20 |
JP5782638B2 (ja) | 2015-09-24 |
US20150148350A1 (en) | 2015-05-28 |
CN104487080A (zh) | 2015-04-01 |
EP2870971A4 (en) | 2016-01-06 |
CN104487080B (zh) | 2017-05-31 |
US9555028B2 (en) | 2017-01-31 |
ES2621898T3 (es) | 2017-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride | |
AU2009286285A1 (en) | Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders | |
KR102578102B1 (ko) | 엔도텔린 수용체 길항제의 국소 안용 제형 | |
CN102639141A (zh) | 用于预防和治疗黄斑变性、糖尿病性视网膜病变和糖尿病性黄斑水肿的组合物和方法 | |
Zhuang et al. | Effect of quercetin on formation of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) | |
AU2006260184A1 (en) | Prophylactic or therapeutic agent for corneal/conjunctival disease | |
EP3744316A1 (en) | Ophthalmic pharmaceutical composition, preparation method therefor and application thereof | |
Chowdhury et al. | ATP-sensitive potassium (KATP) channel openers diazoxide and nicorandil lower intraocular pressure in vivo | |
JP5782638B2 (ja) | 眼疾患の予防・治療薬 | |
Yeu et al. | Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease | |
Huang et al. | MMP9‐Responsive Graphene Oxide Quantum Dot‐Based Nano‐in‐Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization | |
EA035966B1 (ru) | Применение фармацевтической композиции для местного применения для лечения расстройств лакримальной системы и переднего отрезка глаза | |
JP6487609B1 (ja) | 点眼剤 | |
Bao et al. | Pirfenidone ameliorates the formation of choroidal neovascularization in mice | |
Zhang et al. | Aquaporin 5 in the eye: expression, function, and roles in ocular diseases | |
Steinemann et al. | Corneal endothelial decompensation after ocular chemical burn: description of a new finding | |
KR101794225B1 (ko) | 안지오제닌을 유효성분으로 함유하는 각막 내피의 창상 치료용 약학조성물 | |
WO2016076006A1 (ja) | 加齢黄斑変性症予防又は治療剤 | |
Ge et al. | Management of experimental trabeculectomy filtering blebs via crosslinking of the scleral flap inhibited vascularization | |
CN104473915B (zh) | 西维来司他作为治疗癫痫病药物的应用 | |
Albar et al. | Nanophthalmos and hemiretinal vein occlusion: A case report | |
CN113262235B (zh) | 新琼寡糖在治疗眼科疾病方面的新用途 | |
JP6206782B2 (ja) | 人工涙液の組成物 | |
RU2689324C1 (ru) | Способ профилактики пролиферативной витриоретинопатии, развивающейся при отслойке сетчатки в эксперименте на крысах | |
Roy et al. | Ophthalmic combination of SurR9-C84A and trichostatin-A targeting molecular pathogenesis of alkali burn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2013552051 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13816538 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14413455 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20157002946 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013816538 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013816538 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14413455 Country of ref document: US |